

**Food and Drug Administration  
Center for Biologics Evaluation and Research (CBER)**

**January 14, 2016**

**141<sup>st</sup> Vaccines and Related Biological Products Advisory Committee Meeting  
Via Teleconference**

**Office of Vaccines Research and Review (OVRR)  
Division of Viral Products (DVP)  
Laboratory of Method Development (LMD)  
Building 31, Great Room, Salon A  
Silver Spring, MD**

**Live Webcast: <https://collaboration.fda.gov/vrbpacsem1/>**

**AGENDA**

**Open Session**

<b>Time</b>	<b>Presentation/ Presenter</b>
1:00 P.M.	<b>Call to Order and Opening Remarks</b> <b>Introduction of Committee</b> Robert Daum, M.D., Chair  <b>Conflict of Interest Statement</b> Sujata Vijh, Ph.D., DFO
	<b>Topic:</b> <b>Presentations of the Laboratory of Method Development, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research</b>
1:15 P.M.	<b>Overview Of CBER Research/Site Visit Process</b> Carolyn Wilson, PH.D. Associate Director for Research CBER, FDA
1:35 P.M.	<b>Overview of OVRR</b> Konstantin Chumakov, PH.D. Associate Director for Research OVRR, CBER, FDA
1:50 P.M.	<b>Overview of DVP</b> Jerry Weir, PH.D. Director DVP, CBER, FDA
2:00 P.M.	<b>Overview of LMD</b> Steven Rubin, PH.D. Acting Laboratory Chief LMD, DVP, CBER, FDA
2:30 P.M.	<b>Questions</b>
2:35 P.M.	<b>Open Public Hearing (if no speakers, will move directly to closed session)</b>
3:35 P.M.	<b>Closed Session</b>
5:00 P.M.	<b>Adjournment</b>